What is Roth Capital’s Forecast for Tilray FY2025 Earnings?

Tilray Inc (NASDAQ:TLRY) – Stock analysts at Roth Capital dropped their FY2025 earnings per share (EPS) estimates for shares of Tilray in a research note issued on Sunday, January 12th. Roth Capital analyst W. Kirk now expects that the company will post earnings per share of ($0.23) for the year, down from their previous forecast of ($0.18). The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share.

Tilray (NASDAQ:TLRY) last announced its earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). The firm had revenue of $210.90 million during the quarter, compared to analyst estimates of $216.34 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. Tilray’s revenue was up 8.7% on a year-over-year basis.

TLRY has been the topic of several other research reports. Roth Mkm lowered their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th. Canaccord Genuity Group boosted their price objective on shares of Tilray from $2.00 to $3.00 and gave the stock a “buy” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.70.

Tilray Price Performance

Shares of NASDAQ TLRY opened at $1.18 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The business has a 50-day moving average of $1.34 and a 200-day moving average of $1.61. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.37 and a beta of 2.08. Tilray has a fifty-two week low of $1.14 and a fifty-two week high of $2.97.

Insider Buying and Selling

In related news, CFO Carl A. Merton acquired 26,000 shares of Tilray stock in a transaction on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the completion of the transaction, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.87% of the stock is owned by insiders.

Hedge Funds Weigh In On Tilray

Several institutional investors and hedge funds have recently made changes to their positions in TLRY. Bank of Montreal Can increased its position in Tilray by 0.3% during the 3rd quarter. Bank of Montreal Can now owns 2,176,506 shares of the company’s stock worth $3,787,000 after buying an additional 7,406 shares during the period. State Street Corp grew its position in shares of Tilray by 4.7% during the 3rd quarter. State Street Corp now owns 1,961,338 shares of the company’s stock worth $3,452,000 after purchasing an additional 88,079 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Tilray by 1,314.1% in the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock valued at $3,202,000 after buying an additional 1,690,827 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Tilray by 6.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company’s stock valued at $2,953,000 after buying an additional 107,530 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Tilray by 2.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,487,500 shares of the company’s stock valued at $2,617,000 after buying an additional 37,300 shares during the period. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.